Pharmaceutical regulatory data, drug approvals & compliance tracking
Home › Biosimilars
This page provides comprehensive data and analytics for biosimilar tracker. Our database is updated regularly to ensure accuracy and relevance. Our methodology combines automated data collection with expert curation to ensure high-quality, reliable information. Each data point is verified against multiple sources before publication.
Historical data is available for trend analysis, allowing users to identify patterns and forecast future developments. The platform supports custom date ranges and filtering options for deeper analysis. Comparing these figures with historical averages reveals interesting patterns. The current period shows notable deviations from long-term trends in several categories, warranting closer examination.
This page is part of the FDA News data platform, which offers comprehensive coverage across related categories. Navigate using the links above to explore other sections.
| Biosimilar | Reference Drug | Company | Approval | Savings vs Ref |
|---|---|---|---|---|
| Adalimumab-bwwd | Humira | CivicaBio | 2023 | 85% |
| Bevacizumab-bvzr | Avastin | PharmaGen | 2024 | 62% |
| Trastuzumab-anns | Herceptin | BioSame | 2023 | 55% |
| Pegfilgrastim-jmdb | Neulasta | FrequenZ | 2024 | 70% |
| Insulin glargine-yfgn | Lantus | InsulinCo | 2024 | 78% |
Data updated continuously. Last refresh: May 11, 2026 14:30 UTC.
